Advertisement

Rebound insomnia after abrupt clozapine withdrawal

  • Jürgen Staedt
  • Gabriela Stoppe
  • Göran Hajak
  • Eckart Rüther
Original Paper

Abstract

Rebound insomnia has been reported upon discontinuation of benzodiazepines. We describe the first case of a sleep polygraphically documented rebound insomnia with an unusual somatic fatigue syndrome after long-term use of clozapine in a 30-year-old schizophrenic male. The withdrawal symptoms occurred the first day after drug discontinuation and could be stopped by readministering clozapine. In our opinion, the sudden occurrence of the withdrawal symptoms cannot be explained by a dopaminergic hypersensitivityor a cholinergic rebound, but indicates an involvement of GABAergic and perhaps antiglutamatergic properties of clozapine.

Key words

Rebound insomnia Withdrawal symptoms Clozapine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alphs LD, Lee HS (1991) Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 52:346Google Scholar
  2. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R), 3rd edn, revised. American Psychiatric Press; Washington, DCGoogle Scholar
  3. Anderman B, Griffith RW (1977) Clozapine-induced agranulocytosis: a situation report up to 1976. Eur J Clin Pharmacol 11: 199–201Google Scholar
  4. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99:463–472Google Scholar
  5. Borison RL, Diamond BI, Sinha D, Gupta RP, Ajiboye PA (1988) Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 24:260–263Google Scholar
  6. Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Maziere B (1987) In vivo assay for neuroleptic receptor binding in the striatum: positron emission tomography in humans. Br J Psychiatry 151:824–830Google Scholar
  7. Chouinard G, Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137:16–21Google Scholar
  8. Dickson R, Williams R, Dalby JT (1994) Dystonic reaction and relapse with clozapine discontinuation and risperidone initiaton. Can J Psychiatry 39(3):184Google Scholar
  9. Drew KL, O'Connor WT, Kehr J, Ungerstedt U (1990) Regional specificity of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur J Pharmacol 187:385–397Google Scholar
  10. Ekblom B, Eriksson K, Lindstrom LH (1984) Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology 83:293–294Google Scholar
  11. Eklund K (1987) Supersensitivity and clozapine withdrawal. Psychopharmacology 90:135Google Scholar
  12. Gillin JC, Spinweber CL, Johnson LC (1989) Rebound insomnia: a critical review. J Clin Psychopharmacol 9(3):161–172Google Scholar
  13. Graham SR, Kokkinidis L (1993) Clozapine inhibits limbic system kindling: implications for antipsychotic action. Brain Res Bull 30:597–605Google Scholar
  14. Klimke A, Klieser E (1995) The atypical neuroleptic clozapine (Leponex): state of the art and recent clinical aspects. Fortschr Neurol Psychiatrie 63:173–193Google Scholar
  15. Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 160 (Suppl 17):38–40Google Scholar
  16. Lidsky TI, Alter E, Banerjee SP (1991) Effects of clozapine on glutamatergic transmission. Soc Neurosci 17:686Google Scholar
  17. Lieberman JA, Alvir JM (1992) A report of clozapine-induced agranulocytosis in the United States. Drug Safety 7 (Suppl 1): 1–2Google Scholar
  18. Luchins DJ, Freed WJ, Wyatt RJ (1980) The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 137(11): 1395–1398Google Scholar
  19. Meltzer HY, Bastani B, Ramirez LF, Matsubara S (1989) Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Clin Neurosci 238:332–339Google Scholar
  20. Parsa MA, al-Lahham YH, Ramirez LF, Meltzer HY (1993) Prolonged psychotic relapse after abrupt clozapine withdrawal. J Clin Psychopharmacol 13(2):154–155Google Scholar
  21. Perenyi A, Kuncz E, Bagdy G (1986) Early relapse after sudden withdrawal or dose reduction of clozapine. Psychopharmacology 86:244Google Scholar
  22. Rechtschaffen A, Kales A (1968) A manual of standarized terminology, techniques and scoring system for sleep stages of human subjects. Public Health Service, Washington DC, NIH, Pub No 204. US Government Printing OfficeGoogle Scholar
  23. Simpson GM, Lee JH, Shrivastava RK (1978) Clozapine in tardive dyskinesia. Psychopharmacology 56:75–80Google Scholar
  24. Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Munz DL, Emrich D, Rüther E (1995) Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2 receptor alteration. Eur Arch Psychiatry Clin Neurosci 245: 8–10Google Scholar
  25. Ungerstedt R, Ljungberg T (1977) Behavioral, patterns related to dopamine neurotransmission: effects of acute and chronic antipsychotic drugs. In: Costa E, Gessa GL (eds) Advances in biochemical psychopharmacology, vol 16. Raven Press, New York, pp 193–199Google Scholar
  26. Zapletalek M, Preiningerova O, Hanus H (1980) Does clozapine cause dependence? Agressologie 21(A):19–22Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Jürgen Staedt
    • 1
  • Gabriela Stoppe
    • 1
  • Göran Hajak
    • 1
  • Eckart Rüther
    • 1
  1. 1.Department of PsychiatryGeorg August UniversityGöttingenGermany

Personalised recommendations